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項 目 症例１ 症例２ 症例３ 症例４ 症例５ Mean±SD
年齢・性 ７３歳・男 ３４歳・男 ６３歳・男 ４１歳・男 ４０歳・男 全例男性，５０±１７歳
罹病期間（年） １５ ５ ２ ３ ０．３ ５．１±５．８
BMI（kg/m２） ２１．３ ２８．９ ２３．４ ３０．０ ３５．４ ２７．８±５．６
腹囲（cm） ８０ ９２ ８５ １１１ １０５ ９５±１３




なし なし なし なし １／５にあり
高血圧症 あり なし あり あり あり ４／５にあり
脂質代謝異常 あり なし あり あり あり ４／５にあり
食後血糖（mg/dl） ２３６ １９１ １４５ ２６５ １４２ １９６±５５
HbA１C（%） ７．４ １０．１ ７．４ １０．０ ８．３ ８．６±１．３
血清 IRI（μU/ml） ３．０ ５．０ ６．０ n．d． １１．０ ６．３±３．４
尿中 CPR（μg／日） ９５．７ n．d． ６８．０ ９２．７ １２８．０ ９６．１±２４．６
Adiponectin（μg/ml） １．４ ３．９ ３．６ ２．５ ３．４ ３．０±１．０
Leptin（ng/ml） ４．０ ３．９ １．６ ８．９ ９．６ ５．６±３．５








（SU : sulfonylurea, α GI : α-glucosidase inhibitor, Pio : pioglitazone, CaCB : calcium channel blocker, ARB :
angiotensin receptor blocker, α B : α-blocker）
VOL.１１ NO.１ MARCH ２００６ 低Adiponectin血症を呈する２型糖尿病患者に対する
Pioglitazoneの有用性の検討
13



























Tokushima Red Cross Hospital Medical Journal






















































































































































































































































VOL.１１ NO.１ MARCH ２００６ 低Adiponectin血症を呈する２型糖尿病患者に対する
Pioglitazoneの有用性の検討
15












３）Arita Y, Kihara S, Ouchi N et al : Paradoxical
decrease of an adipose-specific protein, adi-
ponectin, in obesity. Biochem Biophys Res
Commun ２５７：７９－８３，１９９９
４）Kumada M, Kihara S, Sumitsuji S et al : Asso-
ciation of hypoadiponectinemia with coronary
artery disease in men. Atheroscler Thromb
Vasc Biol ２３：８５－８９，２００３
５）Lindsay RS, Funahashi T, Hanson RL et al :
Adiponectin and development of type２ diabe-
tes in the Pima Indian population. Lancet ３６０：
５７－５８，２００２
６）Yki-Jarvinen H : Thiazolidinediones. N Eng J Med
３５１：１１０６－１１１８，２００４
７）Maeda N, Takahashi M, Funahashi T et al :
PPARγ ligands increase expression and plasma
concentrations of adiponectin, an adipose-derived
protein. Diabetes ５０：２０９４－２０９９
８）Miyazaki Y, Mahankall A, Wajcberg E et al :
Effect of pioglitazone on circulating adipocy-
tokine level and insulin sensitivity in Type ２





１０）Aronoff S, Rosenblatt S, Braithwaite S et al :
Pioglitazone hydrochloride monotherapy improve
glycemic control in the treatment of patients




Tokushima Red Cross Hospital Medical Journal
／【Ｋ：】Ｓｅｒｖｅｒ／Ｍｅｄｉｃａｌ　Ｊｏｕｒｎａｌ／２００６／原著 金崎淑子　Ｐ１２～１７ 2011年10月24日 13時27分 0秒 20
Evaluation of the Usefulness of Pioglitazone in Type ２ Diabetes Patients Presenting
with Hypoadiponectinemia
Yoshiko KANEZAKI, Yasumi SHINTANI, Chikako MORIYA
Junko MIYAGI, Keiko MIYA, Junichi NAGATA
Division of Metabolism and Endocrinology, Tokushima Red Cross Hospital
The effects of pioglitazone, an insulin-sensitizer, on plasma glucose control and serum adiponectin level were
investigated in patients with type２ diabetes mellitus presenting with hypoadiponectinemia. The subjects were
５ males with type ２ diabetes mellitus with serum adiponectin level less than ４μg/ml. Subjects were aged
５０±１７ years and had a BMI of ２７．８±５．６kg/m２（mean±SD）. The concomitantly used drugs were α GI in １
case, SU + α GI in２ cases and glinide + insulin in１ case. In４ cases, patients were complicated by hyperten-
sion and hyperlipidemia and in１ case by ischemic heart disease. Before the start of pioglitazone therapy, PPG
was ２０９±５３mg/dl, HbA１C was ８．６±１．３％, plasma IRI was ６．３±３．４μU（n＝４）, urinary CPR excretion was
９６±２５μg/day（n＝４）, serum adiponectin was ３．０±１．０μg/ml and serum leptin was ５．４±３．２ng/ml. After the
start of pioglitazone therapy at １５‐３０mg/day, serum adiponectin levels began to rise rapidly in ４ cases and
remained unchanged in only one case（Case４）, with the mean serum adiponectin level changing from３．０±１．０
μg/ml before treatment to ９．２±６．３μg/ml after treatment. plasma glucose control was improved in all cases
after treatment, recording an HbA１C of ７．３±１．０％ after ６ months of treatment. In some cases, slight
improvement in blood pressure and lipid metabolism was also noted. In ２ patients who had been severely
obese（BMI over３０kg/m２）before treatment, weight gain and elevation of serum leptin level were noted after
the start of treatment. In both cases, improvement in plasma glucose control slowed down or worsened from
the ３rd month of treatment on. These results suggest that if patients with hypoadiponectinemia are treated
with pioglitazone, one risk factor for large vessel disorder is reduced due to the drug-induced elevation of
serum adiponectin level, but it is important to continue lifestyle habits unlikely to lead to weight gain or
elevation in serum leptin level, to maintain improved plasma glucose control.
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